Medicare AdvantageCoverageMedium impact
MA08.109c, Crizanlizumab-tmca (Adakveo®)
Independence Blue Cross·Hematology, Pharmacy, Internal Medicine·Pharmacy
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Medicare Advantage policy MA08.109c regarding Crizanlizumab-tmca (Adakveo®) has been reissued effective 06/24/2026. This pharmacy policy update requires immediate review to determine coverage criteria, prior authorization requirements, and billing implications for this sickle cell disease treatment. The specific policy details are not provided in the source material, requiring access to the full policy document for complete billing guidance.
Action Required
By 06/24/2026: Billing and pharmacy teams must access the complete MA08.109c policy document at the provided URL to identify: (1) prior authorization requirements, (2) applicable HCPCS codes for Crizanlizumab-tmca administration, (3) medical necessity criteria, and (4) any coverage limitations. Update billing system and prior authorization workflows accordingly. Communicate requirements to providers managing sickle cell disease patients. Failure to implement coverage requirements may result in claim denials for Medicare Advantage members.